Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study.
Sancho-Saldaña A, Gil-Sánchez A, González-Mingot C, Peralta S, Solana MJ, Torres P, Juanes A, Quibus L, Ruiz E, Sanpedro E, Quirant-Sánchez B, Martínez-Cáceres E, Ramo Tello C, Presas-Rodríguez S, García Rubio S, Baron BP, Ramió-Torrentà L, Sotoca J, González-Suárez I, Eichau S, Prieto-González JM, Blasco Quilez MR, Sabín-Muñoz J, Sánchez-López AJ, Llorens Calatayud G, Calles C, Sempere ÁP, Garcés M, Carmona O, Moral E, Hervás JV, Blanco Y, Sola-Valls N, Tellez Lara N, Forero L, Brieva L. Sancho-Saldaña A, et al. Among authors: martinez caceres e. J Clin Med. 2023 Nov 23;12(23):7243. doi: 10.3390/jcm12237243. J Clin Med. 2023. PMID: 38068295 Free PMC article.
Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies.
Sancho-Saldaña A, Gil Sánchez A, Quirant-Sánchez B, Nogueras L, Peralta S, Solana MJ, González-Mingot C, Gallego Y, Quibus L, Ramo-Tello C, Presas-Rodríguez S, Martínez-Cáceres E, Torres P, Hervás JV, Valls J, Brieva L. Sancho-Saldaña A, et al. J Clin Med. 2022 Apr 29;11(9):2509. doi: 10.3390/jcm11092509. J Clin Med. 2022. PMID: 35566632 Free PMC article.
Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.
Quirant-Sánchez B, Hervás-García JV, Teniente-Serra A, Brieva L, Moral-Torres E, Cano A, Munteis E, Mansilla MJ, Presas-Rodriguez S, Navarro-Barriuso J, Ramo-Tello C, Martínez-Cáceres EM. Quirant-Sánchez B, et al. CNS Neurosci Ther. 2018 Dec;24(12):1175-1184. doi: 10.1111/cns.12851. Epub 2018 Apr 15. CNS Neurosci Ther. 2018. PMID: 29656444 Free PMC article.
Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment.
Quirant-Sánchez B, Presas-Rodriguez S, Mansilla MJ, Teniente-Serra A, Hervás-García JV, Brieva L, Moral-Torres E, Cano A, Munteis E, Navarro-Barriuso J, Martínez-Cáceres EM, Ramo-Tello C. Quirant-Sánchez B, et al. Mediators Inflamm. 2019 Jun 26;2019:8147803. doi: 10.1155/2019/8147803. eCollection 2019. Mediators Inflamm. 2019. PMID: 31346315 Free PMC article.
Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab.
Granell-Geli J, Izquierdo-Gracia C, Sellés-Rius A, Teniente-Serra A, Presas-Rodríguez S, Mansilla MJ, Brieva L, Sotoca J, Mañé-Martínez MA, Moral E, Bragado I, Goelz S, Martínez-Cáceres E, Ramo-Tello C. Granell-Geli J, et al. J Pers Med. 2021 Dec 10;11(12):1347. doi: 10.3390/jpm11121347. J Pers Med. 2021. PMID: 34945819 Free PMC article.
137 results